Organization (Industry)
VIATRIS INC.
ClinicalTrials.gov lists VIATRIS INC. as lead sponsor of 69 trials, counting the companies grouped under it. VIATRIS INC. itself has 2 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 10 registered with a 2026 start date. The dashed outline is the pace from the 9 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Wikimedia Commons contributors, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers VIATRIS INC. and 12 companies grouped under it: 69 lead-sponsored trials (7 its own, 62 in the grouped companies) and 7 legal-entity registrations (3 its own, 4 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (12)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| MEDA Pharma GmbH & Co. KG | 24 | 0 |
| Mylan Bertek Pharmaceuticals | 13 | 0 |
| Oyster Point Pharma, Inc. | 11 | 0 |
| Mylan Pharma UK Ltd. | 5 | 0 |
| Viatris Specialty LLC | 5 | 0 |
Showing 5 of 12 member companies.
Disease areas (119)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pulmonary Disease, Chronic Obstructive | 13 |
| HIV Infections | 9 |
| Diabetes Mellitus | 7 |
| Acquired Immunodeficiency Syndrome | 6 |
| Diabetes Mellitus, Type 1 | 6 |
Showing 5 of 119 disease areas.
Trials by start year as sponsor or collaborator (5)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 1 |
| 2008 | 1 |
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Cenerimod 4 mg | Lupus Erythematosus, Systemic | Phase 2 | 1 |
| Dovprela | Tuberculosis | Not reported | 1 |
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| (alprax) alprazolam | 1 |
| Gabapentin 1200 mg + Oxycodone 20 mg | 1 |
| gabapentin 600 mg | 1 |
| Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate | 1 |
| Oxycodone 20mg | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | not enough data |
Journals published in (76)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 8 |
| Circulation | 5 |
| The Journal of thoracic and cardiovascular surgery | 5 |
| Chest | 4 |
| BMC pulmonary medicine | 2 |
Showing 5 of 76 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 111 | 4 | 2025-08-26 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (31)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 8 |
| GSK plc | Co sponsors trial with | 4 |
| Universität Hamburg | Co sponsors trial with | 1 |
| UCLA Health | Co sponsors trial with | 1 |
| Johnson & Johnson | Co sponsors trial with | 1 |
Showing 5 of 31 relationships.
Latest dated events (567)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 567 events.
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial collaborator | Named in trial inclusion criteria |
| FBRS | Trial sponsor | Named in trial inclusion criteria |
| FBRS | Trial sponsor | Named in trial inclusion criteria |
| FBXO8 | Trial sponsor | Named in trial inclusion criteria |
| FBXO8 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 30 evidence rows.
On Scientist.com
VIATRIS INC. is listed as a research supplier in the Scientist.com network.
Mylan offers generics and specialty pharmaceuticals.
- Website
- www.mylan.com
Not on this page
Checked, with nothing recorded for this organization: sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Mylan on Scientist.com
For prices, more details, or to contact Mylan, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.